PRADAXA (Dabigatran Etexilate Mesylate)
PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. PRADAXA is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with…